

## Clinical Policy: Megestrol Acetate 125 mg/mL Oral Suspension

Reference Number: PA.CP.PMN.179

Effective Date: 10/2018

Last Review Date: 10/2025

### Description

Megestrol acetate 125 mg/mL oral suspension is a progestin.

### FDA Approved Indication(s)

Megestrol acetate is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

Limitation(s) of use:

- Therapy with megestrol acetate for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, and gastrointestinal disorders affecting absorption, endocrine disease, renal disease, or psychiatric diseases.
- Megestrol acetate is not intended for prophylactic use to avoid weight loss.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of PA Health & Wellness® that megestrol acetate is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Request for Megestrol Acetate 125 mg/mL Oral Suspension (must meet all):

1. Member must use megestrol acetate 40 mg/mL oral suspension, unless contraindicated or clinically significant adverse effects are experienced;
2. Dose does not exceed 625 mg (5 mL) per day.

**Approval duration: 12 months**

##### B. Other diagnoses/indications: Not applicable

#### II. Continued Therapy

##### A. Request for Megestrol Acetate 125 mg/mL Oral Suspension (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit or member has previously met all initial approval criteria or the Continuity of Care Policy (PA.PHARM.01) applies;
2. If request is for a dose increase, new dose does not exceed 625 mg (5 mL) per day.

**Approval duration: 12 months**

**B. Other diagnoses/indications:** Not applicable

**III. Diagnoses/Indications for which coverage is NOT authorized:** Not applicable

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

AIDS: acquired immunodeficiency syndrome

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

| Drug Name                  | Dosing Regimen   | Dose Limit/<br>Maximum Dose |
|----------------------------|------------------|-----------------------------|
| megestrol acetate 40 mg/mL | 400 to 800 mg QD | 800 mg/day                  |

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): hypersensitivity, known or suspected pregnancy
- Boxed Warning(s): none reported

*Appendix D: General Information*

- Megestrol Acetate 125 mg/mL Oral Suspension is not equivalent to other formulations on a mg-per-mg basis (e.g., megestrol acetate 40 mg/mL).

**V. Dosage and Administration**

| Indication  | Dosing Regimen                            | Maximum Dose          |
|---|---|-----------------------|
| Anorexia, cachexia, or unexplained significant weight loss associated with AIDS | 625 mg PO QD (5 mL or one teaspoon daily) | 625 mg (5 mL) per day |

**VI. Product Availability**

Oral suspension: 625 mg/5 mL (125 mg/mL)

**VII. References**

1. Megestrol Acetate Oral Suspension Prescribing Information. Paramus, NJ: TWI Pharmaceutical, Inc.; March 2023. Available at: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=2dc921d5-e423-4379-a345-151e87d13651&type=pdf>. July 9, 2025.
2. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. *Cochrane Database Syst Rev.* 2013;2013(3):CD004310. Published 2013 Mar 28.

**CLINICAL POLICY**  
**Megesterol Acetate 125 mg/mL Oral Suspension**



3. Nemcheck PM, Polsky B, and Gottlieb MS. Treatment guidelines for HIV-associated wasting. *Subspecialty clinicals: infectious diseases*. April 2000;75(4):p386-394.
4. *Clinical Pharmacology* [database online] Philadelphia, PA: Elsevier. Updated periodically Available at <http://www.clinicalkey.com/pharmacology>. Accessed August 13, 2025.

| Reviews, Revisions, and Approvals  | Date    |
|--|---------|
| Policy created   | 10/2018 |
| 4Q 2019 annual review: No changes per Statewide PDL implementation 01-01-2020  | 10/2019 |
| 4Q 2020 annual review: References reviewed and updated.  | 07/2020 |
| 4Q 2021 annual review: no significant changes; changed megestrol 40 mg/mL requirement to “Member must use...” language; references reviewed and updated.   | 10/2021 |
| 4Q 2022 annual review: no significant changes; references reviewed and updated.  | 10/2022 |
| 4Q 2023 annual review: no significant changes; references reviewed and updated.  | 10/2023 |
| 4Q 2024 annual review: removed brand Megace ES from policy due to product discontinuation; clarified that this policy is applicable to generic megestrol acetate 125 mg/mL oral solution; references reviewed and updated. | 10/2024 |
| 4Q 2025 annual review: no significant changes; references reviewed and updated.  | 10/2025 |